Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials

doi:10.1016/j.jaad.2016.02.965

Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.965 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB247

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Age Group ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Drugs & Aging ◽

10.1007/s40266-018-0520-z ◽

2018 ◽

Vol 35 (2) ◽

pp. 135-144 ◽

Cited By ~ 23

Author(s):

Andreas Körber ◽

Charis Papavassilis ◽

Vaishali Bhosekar ◽

Maximilian Reinhardt

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Elderly Subjects ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Studies

Download Full-text

Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.010 ◽

2004 ◽

Vol 50 (3) ◽

pp. P1 ◽

Cited By ~ 5

Author(s):

Kenneth Gordon ◽

David Pariser ◽

Richard Langley ◽

Ivor Caro

Keyword(s):

Plaque Psoriasis ◽

Large Cohort ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Secukinumab efficacy and safety in Asian subjects with moderate to severe plaque psoriasis: Pooled analysis from the FIXTURE and ERASURE phase III clinical studies

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.994 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB249

Keyword(s):

Plaque Psoriasis ◽

Clinical Studies ◽

Pooled Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and Safety of Moxifloxacin in Hospitalized Patients with Secondary Peritonitis: Pooled Analysis of Four Randomized Phase III Trials

Surgical Infections ◽

10.1089/sur.2013.045 ◽

2014 ◽

Vol 15 (5) ◽

pp. 567-575 ◽

Cited By ~ 3

Author(s):

Jan J. De Waele ◽

Jose M. Tellado ◽

Günter Weiss ◽

Jeffrey Alder ◽

Frank Kruesmann ◽

...

Keyword(s):

Pooled Analysis ◽

Hospitalized Patients ◽

Secondary Peritonitis ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trials

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0353-x ◽

2018 ◽

Vol 19 (3) ◽

pp. 457-457 ◽

Cited By ~ 1

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Christopher E. M. Griffiths ◽

Luis Puig ◽

Jamie Weisman ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Phase Iii ◽

Efficacy And Safety ◽

Two Phase ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

Postgraduate Medicine ◽

10.1080/00325481.2015.1027132 ◽

2015 ◽

Vol 127 (5) ◽

pp. 419-428 ◽

Cited By ~ 2

Author(s):

James Thrasher ◽

David S. Kountz ◽

Susanne Crowe ◽

Hans-Juergen Woerle ◽

Maximilian von Eynatten

Keyword(s):

Type 2 Diabetes ◽

African American ◽

Pooled Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Black African ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Phase Iii Trials

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.07.040 ◽

2016 ◽

Vol 75 (6) ◽

pp. 1162-1170.e3 ◽

Cited By ~ 29

Author(s):

Steven R. Feldman ◽

Diamant Thaçi ◽

Melinda Gooderham ◽

Matthias Augustin ◽

Claudia de la Cruz ◽

...

Keyword(s):

Quality Of Life ◽

Plaque Psoriasis ◽

Phase Iii ◽

Health Related Quality ◽

Severe Plaque Psoriasis ◽

Related Quality ◽

Phase Iii Trials ◽

Health Related

Download Full-text

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.01.017 ◽

2016 ◽

Vol 38 (4) ◽

pp. 843-862.e9 ◽

Cited By ~ 18

Author(s):

Soichi Sakai ◽

Kohei Kaku ◽

Yutaka Seino ◽

Nobuya Inagaki ◽

Masakazu Haneda ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Sglt2 Inhibitor ◽

Japanese Patients ◽

Pooled Analysis ◽

Phase Iii ◽

Baseline Body Mass Index ◽

Efficacy And Safety ◽

Phase Iii Trials

Download Full-text